Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Neurosci ; 6: 65, 2005 Nov 23.
Article in English | MEDLINE | ID: mdl-16305740

ABSTRACT

BACKGROUND: The megencephaly mouse, mceph/mceph, is epileptic and displays a dramatically increased brain volume and neuronal count. The responsible mutation was recently revealed to be an eleven base pair deletion, leading to a frame shift, in the gene encoding the potassium channel Kv1.1. The predicted MCEPH protein is truncated at amino acid 230 out of 495. Truncated proteins are usually not expressed since nonsense mRNAs are most often degraded. However, high Kv1.1 mRNA levels in mceph/mceph brain indicated that it escaped this control mechanism. Therefore, we hypothesized that the truncated Kv1.1 would be expressed and dysregulate other Kv1 subunits in the mceph/mceph mice. RESULTS: We found that the MCEPH protein is expressed in the brain of mceph/mceph mice. MCEPH was found to lack mature (Golgi) glycosylation, but to be core glycosylated and trapped in the endoplasmic reticulum (ER). Interactions between MCEPH and other Kv1 subunits were studied in cell culture, Xenopus oocytes and the brain. MCEPH can form tetramers with Kv1.1 in cell culture and has a dominant negative effect on Kv1.2 and Kv1.3 currents in oocytes. However, it does not retain Kv1.2 in the ER of neurons. CONCLUSION: The megencephaly mice express a truncated Kv1.1 in the brain, and constitute a unique tool to study Kv1.1 trafficking relevant for understanding epilepsy, ataxia and pathologic brain overgrowth.


Subject(s)
Brain/abnormalities , Frameshift Mutation , Gene Expression Regulation/genetics , Kv1.1 Potassium Channel/genetics , Kv1.1 Potassium Channel/metabolism , Animals , Blotting, Western/methods , Brain/pathology , Cell Line , Dose-Response Relationship, Radiation , Electric Stimulation/methods , Glycosylation , Humans , Immunohistochemistry/methods , Immunoprecipitation/methods , Kv1.1 Potassium Channel/immunology , Kv1.2 Potassium Channel/metabolism , Membrane Potentials/genetics , Membrane Potentials/physiology , Membrane Potentials/radiation effects , Mice , Mice, Inbred BALB C , Mice, Knockout , Mice, Mutant Strains , Oocytes/physiology , Patch-Clamp Techniques/methods , Peptide Fragments/immunology , Peptide Fragments/metabolism , Protein Structure, Tertiary/genetics , Protein Transport/genetics , Transfection/methods , Xenopus
2.
Eur J Neurosci ; 18(12): 3218-30, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14686896

ABSTRACT

The mouse model for megencephaly, mceph/mceph, carries a truncating deletion in the Shaker-related voltage gated potassium channel gene 1. Affected mice display neurological disturbances and motor dysfunctions. Symptoms begin to show at 3-4 weeks of age. The cause of the brain enlargement is not clear. To elucidate early events in the development of the disease we used magnetic resonance imaging (MRI) to quantify, over time, the increase in size of several discrete brain regions in the same mice at 3, 8 and 12 weeks of age. We also analysed markers for neuropeptides and growth factors to explore their possible involvement at an early stage. The results show an enlargement of the total coronal area of the brain already at 3 weeks of age. Total brain volume, ventral cortex, hippocampal formation and cerebral cortex were enlarged at 8 weeks and onwards. Thalamus, brainstem, cerebellum and spinal cord did not differ from controls even at 12 weeks. We also report distinct disturbances in the expression of brain-derived neurotrophic factor, insulin-like growth factor binding protein 6 and several neuropeptides at 2 and 3 weeks of age, that is, before an obvious behavioural phenotype can be observed. These results provide an objective description of the size changes in different brain regions of the mceph/mceph mouse, and suggest that certain molecules could be involved in the early processes underlying these changes.


Subject(s)
Brain/abnormalities , Brain/pathology , Gene Expression Regulation, Developmental/genetics , Nervous System Malformations/genetics , Nervous System Malformations/pathology , Potassium Channels, Voltage-Gated , Potassium Channels/deficiency , Aging/genetics , Aging/metabolism , Animals , Biomarkers , Brain/growth & development , Cell Differentiation/genetics , Cerebral Cortex/abnormalities , Cerebral Cortex/cytology , Cerebral Cortex/metabolism , Female , Growth Substances/genetics , Hippocampus/abnormalities , Hippocampus/cytology , Hippocampus/metabolism , Hypertrophy/genetics , Hypertrophy/metabolism , In Situ Hybridization , Kv1.1 Potassium Channel , Magnetic Resonance Imaging , Male , Mice , Mice, Neurologic Mutants , Nervous System Malformations/metabolism , Neuropeptides/genetics , Potassium Channels/genetics , RNA, Messenger/metabolism , Up-Regulation/genetics
3.
Eur J Neurosci ; 18(12): 3231-40, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14686897

ABSTRACT

The megencephaly mouse, mceph/mceph, displays dramatically increased brain volume and hypertrophic brain cells. Despite overall enlargement, the mceph/mceph brain appears structurally normal, without oedema, hydrocephaly or leukodystrophy, and with only minor astrocytosis. Furthermore, it presents striking disturbances in expression of trophic and neuromodulating factors within the hippocampus and cortex. Using a positional cloning approach we have identified the mceph mutation. We show that mceph/mceph mice carry an 11-base-pair deletion in the gene encoding the Shaker-like voltage-gated potassium channel subtype 1, Kcna1. The mutation leads to a frame shift and the predicted MCEPH protein is truncated at amino acid 230 (out of 495), terminating with six aberrant amino acids. The expression of Kcna1 mRNA is increased in the mceph/mceph brain. However, the C-terminal domains of the corresponding Kv1.1 protein are absent. The putative MCEPH protein retains only the N-terminal domains for channel assembly and may congregate nonfunctional complexes of multiple Shaker-like subunits. Indeed, whereas Kcna2 and Kcna3 mRNA expression is normal, the mceph/mceph hippocampus displays decreased amounts of Kv1.2 and Kv1.3 proteins, suggesting interactions at the protein level. We show that mceph/mceph mice have disturbed brain electrophysiology and experience recurrent behavioural seizures, in agreement with the abnormal electrical brain activity found in Shaker mutants. However, in contrast to the commonly demonstrated epilepsy-induced neurodegeneration, we find that the mceph mutation leads to seizures with a concomitant increase in brain size, without overt neural atrophy.


Subject(s)
Brain/abnormalities , Brain/metabolism , Frameshift Mutation/genetics , Nervous System Malformations/genetics , Potassium Channels, Voltage-Gated , Potassium Channels/deficiency , Amino Acid Sequence/genetics , Animals , Brain/growth & development , Down-Regulation/genetics , Gene Deletion , Hypertrophy/genetics , Hypertrophy/metabolism , Kv1.1 Potassium Channel , Kv1.2 Potassium Channel , Kv1.3 Potassium Channel , Membrane Potentials/genetics , Mice , Mice, Mutant Strains , Molecular Sequence Data , Molecular Weight , Nerve Degeneration/genetics , Nerve Degeneration/metabolism , Nervous System Malformations/metabolism , Potassium Channels/genetics , Potassium Channels/metabolism , Protein Structure, Tertiary/genetics , Protein Subunits/genetics , RNA, Messenger/metabolism , Seizures/genetics , Seizures/metabolism
4.
Genes Dev ; 17(24): 3036-47, 2003 Dec 15.
Article in English | MEDLINE | ID: mdl-14681209

ABSTRACT

The retinoid X receptor (RXR) is essential as a common heterodimerization partner of several nuclear receptors (NRs). However, its function as a bona fide receptor for endogenous ligands has remained poorly understood. Such a role would depend on the existence of RXR activating ligands in vivo and on the ability of such ligands to influence relevant biological functions. Here we demonstrate the presence of endogenous RXR ligands in the embryonic central nervous system (CNS) and show that they can activate heterodimers formed between RXR and the orphan NR Nurr1 in vivo. Moreover, RXR ligands increase the number of surviving dopaminergic cells and other neurons in a process mediated by Nurr1-RXR heterodimers. These results provide evidence for a role of Nurr1 as a ligand-independent partner of RXR in its function as a bona fide ligand-activated NR. Finally, our findings identify RXR-Nurr1 heterodimers as a potential target in the treatment of neurodegenerative disease.


Subject(s)
Brain/embryology , DNA-Binding Proteins/metabolism , Fungal Proteins , Neurons/metabolism , Receptors, Retinoic Acid/metabolism , Signal Transduction/physiology , Transcription Factors/metabolism , Animals , Anticholesteremic Agents/pharmacology , Antineoplastic Agents/pharmacology , Cell Survival/drug effects , Cells, Cultured , Choriocarcinoma/metabolism , Choriocarcinoma/pathology , DNA-Binding Proteins/genetics , Dopamine Agents/pharmacology , Female , Ligands , Male , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Neurons/drug effects , Nuclear Receptor Subfamily 4, Group A, Member 2 , Organic Chemicals , Rats , Receptors, Retinoic Acid/genetics , Retinoid X Receptors , Transcription Factors/genetics , Tretinoin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...